Squadron Capital Management LLC
Squadron Capital Management LLC reported 43 holdings worth US$322M as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 14, 2026
Squadron Capital Management LLC reported 43 holdings worth US$322M as of Jun 30, 2026. Largest: Relmada Therapeutics, Inc., C4 Therapeutics, Inc. and Cogent Biosciences, Inc. Filed Aug 14, 2026 (Form 13F).
- Holdings
- 43
- Value as reported
- US$322M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Relmada Therapeutics, Inc. | 7.35M | US$50.9M | 15.8% |
| C4 Therapeutics, Inc. | 7.2M | US$33.6M | 10.4% |
| Cogent Biosciences, Inc. | 865K | US$33.5M | 10.4% |
| Kodiak Sciences Inc | 500K | US$19.5M | 6.0% |
| Relay Therapeutics, Inc. | 970K | US$18.1M | 5.6% |
| Zentalis Pharmaceuticals, Inc. | 3.7M | US$17.9M | 5.6% |
| Edgewise Therapeutics, Inc. | 290K | US$11.8M | 3.7% |
| Maze Therapeutics, Inc. | 335K | US$10M | 3.1% |
| Inventiva Sa | 2.44M | US$9.2M | 2.9% |
| Enliven Therapeutics, Inc. | 160K | US$8.12M | 2.5% |
| Palisade Bio, Inc. | 3M | US$6.27M | 1.9% |
| Inhibikase Therapeutics, Inc. | 3M | US$6.09M | 1.9% |
| Forte Biosciences, Inc. | 225K | US$4.78M | 1.5% |
| Assembly Biosciences, Inc. | 160K | US$4.4M | 1.4% |
| Promis Neurosciences Inc. | 325K | US$4.28M | 1.3% |
| Contineum Therapeutics, Inc. | 260K | US$4.26M | 1.3% |
| Definium Therapeutics, Inc. | 85,000 | US$4M | 1.2% |
| Bioage Labs, Inc. | 155K | US$3.8M | 1.2% |
| Rezolute, Inc. | 403K | US$2.1M | 0.65% |
| Lipocine Inc. | 810K | US$2.07M | 0.64% |
| Cue Biopharma, Inc. | 50,000 | US$1.58M | 0.49% |
| Calcimedica, Inc. | 1.24M | US$1.28M | 0.40% |
| Pasithea Therapeutics Corp. | 1M | US$515K | 0.16% |
| Inmed Pharmaceuticals Inc. | 325K | US$504K | 0.16% |
| Neumora Therapeutics, Inc. | 100K | US$170K | 0.05% |
| Nextcure, Inc. | 64,464 | US$103K | 0.03% |
| Werewolf Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Abivax Sa | 0 | US$0 | 0.00% |
| Alx Oncology Holdings Inc. | 0 | US$0 | 0.00% |
| Context Therapeutics Inc. | 0 | US$0 | 0.00% |
| Eupraxia Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
| Kalvista Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
| Nektar Therapeutics | 0 | US$0 | 0.00% |
| Neuphoria Therapeutics Inc. | 0 | US$0 | 0.00% |
| Scynexis, Inc. | 0 | US$0 | 0.00% |
| Spruce Biosciences, Inc. | 0 | US$0 | 0.00% |
| Therapeuticsmd, Inc. | 0 | US$0 | 0.00% |
| Traws Pharma, Inc. | 0 | US$0 | 0.00% |
Source
View original at SEC
Related